Neurofilament light chain (NfL) is a key biomarker of neurodegeneration, enabling researchers to track neuronal damage and disease progression in mouse models of neurological disorders. Reliable biomarker measurement is essential for translating preclinical findings into clinical applications.

This publication brief explores how Simoa® technology provides ultra-sensitive NfL detection in preclinical research across multiple disease models, including:

• Alzheimer’s disease (AD)
• Huntington’s disease (HD)
• Mild traumatic brain injury (mTBI)
• Stroke
• Neurotoxicity

The Simoa NfL assay enables precise measurement of NfL in minimal sample volumes, supporting preclinical and clinical research while reducing animal use.

Download the full publication brief to explore how Simoa technology is advancing biomarker discovery in neurodegenerative disease research.